State Street SPDR S&P Pharmaceuticals ETF
XPH
61 hedge funds and large institutions have $84.6M invested in State Street SPDR S&P Pharmaceuticals ETF in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 17 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
8.9% less ownership
Funds ownership: 52.78% → 43.87% (-8.9%)
16% less funds holding
Funds holding: 73 → 61 (-12)
22% less capital invested
Capital invested by funds: $108M → $84.6M (-$23.5M)
58% less call options, than puts
Call options by funds: $366K | Put options by funds: $878K
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.12M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.86M |
| 3 |
CI
CX Institutional
Auburn,
Indiana
|
+$819K |
| 4 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$700K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$431K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$20.9M |
| 2 |
Morgan Stanley
New York
|
-$2.41M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$1.46M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.41M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.25M |
XPH Hedge Fund Activity: Q1 2023 in Review
61 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2023, worth a combined $84.6M — down 22% from $108M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of XPH and 6 opened new positions — a net loss of 11 holders — while 17 trimmed existing stakes and 18 added.
The largest buyer was Goldman Sachs, adding an estimated $2.12M. The largest seller was UBS Group, cutting an estimated $20.9M.
- 61 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2023, down from 73 in Q4 2022.
- Funds reported $84.6M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2023, down 22% quarter-over-quarter.
- 6 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2023 and 17 closed out, a net change of -11 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2023 was Goldman Sachs, an estimated $2.12M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2023 was UBS Group, an estimated $20.9M sold.
Based on aggregated 13F filings for Q1 2023.